Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Completed · Phase 2 · Has a placebo group

Conditions studied: Choroidal Neovascularization, Age-related Macular Degeneration

In brief

The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Key facts

Study ID

NCT02358889

Run by

Iconic Therapeutics, Inc.

People needed

88

Starts

2015-02-01

Expected to finish

2016-09-01

Last updated by the study team

2020-09-24

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females of any race at least 50 years of age
• Active primary Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) in the study eye
• Best Corrected Visual Acuity (BCVA) of 70 to 24 letters (worse than 20/40 up to 20/320) in the study eye

You may not qualify if…

• Monocular patient or patient with a BCVA of 35 or fewer letters (20/200 or worse) in the better seeing eye
• Any prior treatment of CNV or advanced AMD in the study eye, except for dietary supplements or vitamins
• Any intraocular or ocular surface surgery (including cataract surgery and laser procedures) in the study eye within 3 months
• Vitrectomy in the study eye
• Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)

Where it is running

• Study site — Palo Alto, California, United States
• Study site — San Francisco, California, United States
• Study site — Santa Ana, California, United States
• Study site — Golden, Colorado, United States
• Study site — Boynton Beach, Florida, United States
• Study site — Fort Myers, Florida, United States
• Study site — Panama City, Florida, United States
• Study site — Sarasota, Florida, United States
• Study site — Stuart, Florida, United States
• Study site — Winter Haven, Florida, United States
• Study site — Augusta, Georgia, United States
• Study site — Paducah, Kentucky, United States
• Study site — Baltimore, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — Detroit, Michigan, United States
• Study site — Jackson, Michigan, United States
• Study site — Royal Oak, Michigan, United States
• Study site — West Bloomfield, Michigan, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Bloomfield, New Jersey, United States
• Study site — Brooklyn, New York, United States
• Study site — Hauppauge, New York, United States
• Study site — Syracuse, New York, United States
• Study site — Ashland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.